NCT06222164

Brief Summary

Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,000

participants targeted

Target at P75+ for all trials

Timeline
14mo left

Started Mar 2024

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress65%
Mar 2024Jun 2027

First Submitted

Initial submission to the registry

January 15, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 24, 2024

Completed
2 months until next milestone

Study Start

First participant enrolled

March 30, 2024

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 30, 2027

Expected
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2027

Last Updated

May 4, 2025

Status Verified

May 1, 2025

Enrollment Period

3 years

First QC Date

January 15, 2024

Last Update Submit

May 2, 2025

Conditions

Hematologic Diseases

Keywords

residual samples hematologic diseases

Outcome Measures

Primary Outcomes (1)

  • Enrollment

    N=2000

    3 years

Study Arms (1)

Residual Specimens

Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing

You may qualify if:

  • Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing
  • Donor Age ≥ 18 years

You may not qualify if:

  • Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM
  • The specimens/samples have previously been enrolled in a clinical study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

LabPMM

San Diego, California, 92121, United States

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing.

MeSH Terms

Conditions

Hematologic Diseases

Condition Hierarchy (Ancestors)

Hemic and Lymphatic Diseases

Central Study Contacts

Andrew Schut

CONTACT

+1 858.224.6600aschut@invivoscribe.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 15, 2024

First Posted

January 24, 2024

Study Start

March 30, 2024

Primary Completion (Estimated)

March 30, 2027

Study Completion (Estimated)

June 30, 2027

Last Updated

May 4, 2025

Record last verified: 2025-05

Locations

US(1)